The increased cash runway reduces near-term dilution risk, but the growing net loss indicates continued burn rate. Monitor upcoming FDA submission in Q2 2026 for PH-762 as the next catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 6 $1.16entry
- T+1 · 8mo ago +4.31%α +3.46% · $1.21
- T+5 · 8mo ago +0.86%α +2.39% · $1.17
- T+20 · 8mo ago +8.62%α +10.67% · $1.26
- T+60 · 6mo ago −2.59%α −15.37% · $1.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Phio Pharmaceuticals reported its 2025 financial results, highlighting a successful year with completion of the PH-762 Phase 1b trial, $23.7 million in net proceeds from financings and warrant exercises, and an extended cash runway into the first half of 2027. The company reported a net loss of $8.7 million for 2025, up from $7.2 million in 2024, due to increased R&D and G&A spending.
Key Financial Metrics
Key Facts
- Completed Phase 1b dose-escalation trial for lead candidate PH-762 with favorable safety and tolerability data
- Raised $23.7 million in net proceeds during 2025 through equity financings and warrant exercises
- Cash position increased to $21.0 million at year-end 2025 from $5.4 million at year-end 2024
- Cash runway extended into the first half of 2027
- Net loss increased to $8.7 million in 2025 from $7.2 million in 2024
- R&D expenses increased 27% year-over-year; G&A expenses increased 23% year-over-year
Financial Impact
Net loss increased by $1.55 million year-over-year, while cash position grew by $15.6 million due to financings
Risk Factors
- Continuing net losses and cash burn despite recent financing
- Clinical development risks for PH-762 in later-stage trials
- Dependence on future financings or partnerships for long-term funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-007071 |
| Document: phio20251215_8k.htm | 0001437749-26-007071 |
| Document: 0001437749-26-007071-index-headers.html | 0001437749-26-007071 |
| Document: 0001437749-26-007071-index.html | 0001437749-26-007071 |
| Document: 0001437749-26-007071.txt | 0001437749-26-007071 |
Track record
7 reports on PHIO
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.8013 to $0.7710 Now $0.7520 +6.15% ▲ +3.78% +6.38% vs SPY
- Oct 13, 20264w ago 8-K Neutral 3/10 Entry $0.9345 to $0.8921 Now $0.7520 −19.53% ▼ −4.54% −3.39% vs SPY
- Sep 14, 20269w ago 8-K Bullish 5/10 Entry $1.03 to $1.01 Now $0.7520 −26.99% ▼ −1.94% −2.05% vs SPY
- Aug 14, 202613w ago DEFA14A Neutral 3/10 Entry $1.06 to $1.17 Now $0.7520 −29.06% ▲ +10.38% +11.57% vs SPY
- Apr 8, 202631w ago 8-K Neutral 5/10 Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
- Apr 8, 202631w ago 424B5 Neutral 5/10 Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
- Mar 5, 202636w ago 8-K Mixed 6/10 Viewing Entry $1.16 to $1.17 Now $0.7520 −35.17% ▲ +0.86% +2.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers